Why the study?
Does combined ETA receptor blockade and ACE inhibition improve hemodynamics and cardiac remodeling in rats with CHF after MI?
Does combined ETA receptor blockade and ACE inhibition improve hemodynamics and cardiac remodeling in rats with CHF after MI?
In a rat model of post-MI heart failure, combined ETA receptor blockade and ACE inhibition provided additive benefits on hemodynamics, fibrosis, and fetal gene expression compared to monotherapy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for dual ETA/ACE inhibition in experimental CHF; leaves open translation to human therapy.
OBJECTIVES: We investigated the effects of long-term endothelin A (ET(A)) receptor blockade and ACE inhibition, either alone or in combination, on the hemodynamics, neurohormonal activation and cardiac remodeling in rats with congestive heart failure (CHF) after extensive myocardial infarction (MI). METHODS: Rats were treated with placebo, the ET(A) antagonist LU135252 (30 mg/kg/d), the ACE inhibitor trandolapril (0.3 mg/kg/d), or a combination of both for 11 weeks, starting 7 days after MI. RESULTS: Despite comparable effects on left ventricular (LV) systolic pressure among all drug treatments, only combined ET(A) and ACE inhibition significantly reduced LV end-diastolic pressure (P<0.01), improved LV dP/dt(max) (P<0.01) and normalized sympathetic activation (P<0.05) in rats with CHF. The combination therapy was more effective in reducing type I and III collagen mRNA levels, MMP-2 zymographic activity and collagen accumulation in the surviving LV myocardium. Moreover, the increases in cardiac beta-myosin heavy chain and skeletal alpha-actin mRNAs, markers of hypertrophy or failure, were attenuated to a greater degree by the combination therapy than monotherapy, whereas right ventricular hypertrophy and ANF mRNA upregulation were significantly (P<0.01) prevented only by combined ET(A) and ACE inhibition. CONCLUSION: Long-term combined ET(A) receptor and ACE inhibition improved cardiac failure after extensive MI more effectively than monotherapy. We show additive effects on LV fibrosis and fetal gene expression. ET(A) receptor antagonists could be a therapeutical option in CHF in addition to an ACE inhibitor.
No takes yet. Share an insight, caveat, or question.
Daniela Fraccarollo (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: